Advertisement
Table 2 Prognostic tools relating to brachytherapy
| Author | Model type | Variables | Variable readily available? | Validation (I/E) | Accuracy | Metric | Sample size (events) | Outcome | Treatment |
|---|---|---|---|---|---|---|---|---|---|
| Frank [25] | Survival (Nomogram presented) | Biopsy gleason score, clinical stage, EBRT, pre-treatment PSA, | Yes | External validation of Prostogram | 0.49; 95% CI 0.37–0.61 | c-index | 208 (15) | 5 year BFFF | Brachytherapy |
| Kaplan [12] | Survival (Nomogram presented) | Kattan’s: Pretreatment PSA level, Gleason score, clinical stage, adjuvant EBRT | Yes | External validation of Kattan | 0.51 | c-index | 747 (31) | BFFF | 125 iodine brachytherapy |
| Frank [47] | Survival (Nomogram presented) | Pretreatment PSA level, Gleason sum score, T stage, and EBRT | Yes | External validation of Prostogram | 0.66 | c-index | 683 (29) | BCF | Brachytherapy |
| Zelefsky [10] | Proportional hazards regression (Nomogram presented) | Clinical stage, Gleason, pretreatment PSA | Yes | Not stated | 0.70 | c-index | 1466 (NR) | BCF | Brachytherapy |
| Potters [16] | Survival (Cox,Nomogram presented) | Clinical stage, Biopsy Gleason sum, Isotope used, EBRT, D90, pretreatment PSA | No, includes isotope used, D90 | Internal (bootstrapping) | 0.71 | c-index | 5931 (NR) | 9-year BFFF | Brachytherapy |
| D’Amico [42] | Survival Model (Fine and Gray) | Year of brachytherapy, Log (PSA)per unit increase, Gleason score, Age | Yes | Not stated | Not stated | NA | 221 (32) | PCSM and presence of hormone-refractory metastatic prostate cancer | Brachytherapy |
| Sylvester [57] | Survival model (Cox) | PSA only (<10, 10.1–19.9, >20) | Yes | Not stated | Not stated | NA | 215 (NR) | 15 year BFFF | Brachytherapy |
| Sylvester [57] | Survival model (Cox) | PSA only (<10, 10.1–19.9, >20) | Yes | Not stated | Not stated | NA | 215 (NR) | 15 year PCSM | Brachytherapy |
| Sylvester [57] | Survival model (Cox) | PSA only (<10, 10.1–19.9, >20) | Yes | Not stated | Not stated | NA | 215 (NR) | 15 year OS. | Brachytherapy |
| Bittner [27] | Survival model (Cox) | Number of biopsy cores, PSA, Gleason score, % positive biopsies, V100, EBRT, Risk group, hypertension, Tobacco use, perineural invasion | No, tobacco use, V100, hypertension included. | Not stated | Not stated | NA | 1613 (NR) | BFFF | Brachytherapy |
| Bittner [27] | Survival model (Cox) | PSA, Gleason score, % positive biopsies, EBRT, Risk group, hypertension | No, hypertension | Not stated | Not stated | NA | 1613 (NR) | PCSM | Brachytherapy |
| Bittner [27] | Survival model (Cox) | Number of biopsy cores, age at implant, BMI, V100, D90, EBRT, Risk group, hypertension, diabetes, Tobacco use | No, BMI, V100, D90, hypertension, diabetes included | Not stated | Not stated | NA | 1613 (NR) | OS | Brachytherapy |
| Cooperberg [39] | Survival model (Cox) | CAPRA scores (based on PSA, Biopsy Gleason, Age at diagnosis, clinical tumour stage and % biopsy cores positive for cancer) | Yes | Not stated | Not stated | NA | 1441 (17) | PCSM | Brachytherapy |
| Yoshida [15] | Survival model | PRIX score derived from PSA, Gleason and clinical stage | Yes | External | Not stated | NA | 100 (9) | 5 year BCF | HDR-ISBT |
| Yoshida [15] | Survival model | PRIX score derived from PSA, Gleason and clinical stage | Yes | External | Not stated | NA | 100 (9) | 5 year OS | HDR-ISBT |
| Marshall [11] | Survival model (Cox) | Age, Risk group, hormone treatment, Total BED | Yes | Not stated | Not stated | NA | 2495 (251) | BCF | Brachytherapy |
